Nkarta Inc

NASDAQ NKTX

Data sourced from

and

Daily

Download Data

Nkarta Inc Market Capitalization on June 03, 2024: USD 481.29 M

Nkarta Inc Market Capitalization is USD 481.29 M on June 03, 2024, a 101.36% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.

Nkarta Inc 52-week high Market Capitalization is USD 781.03 M on March 27, 2024, which is 62.28% above the current Market Capitalization.
Nkarta Inc 52-week low Market Capitalization is USD 562.91 K on March 14, 2024, which is -99.88% below the current Market Capitalization.
Nkarta Inc average Market Capitalization for the last 52 weeks is USD 275.58 M.

NASDAQ: NKTX

Nkarta Inc

CEO	Mr. Paul J. Hastings
IPO Date	July 10, 2020
Location	United States
Headquarters	6000 Shoreline Court, South San Francisco, CA, United States, 94080
Employees	150
Sector	Healthcare
Industry	Biotechnology

Description

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Key trends